LinkedIn
WebsiteIntroduction
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company headquartered in Seattle, Washington. Established in 2016, the firm specializes in the development of bispecific and trispecific immunotherapies aimed at treating blood and solid tumor malignancies. Using its proprietary ADAPTIR and ADAPTIR-FLEX platforms, Aptevo engineers novel mechanisms of action—such as redirected T-cell cytotoxicity and T-cell co-stimulation—to enhance the body’s immune response against cancer cells.
Corporate Structure
As of December 2025, Aptevo employs between 51 and 200 professionals across research, clinical development, quality, manufacturing, and corporate functions. The executive team is led by President and Chief Executive Officer Marvin L. White, whose prior roles include CFO of LillyUSA and St. Vincent Health. Jeff Lamothe serves as Executive Vice President and Chief Operating Officer, overseeing clinical, R&D, manufacturing, and operations. Senior Vice President and Chief Financial Officer Daphne Taylor manages all financial reporting and strategic planning, while Chief Medical Officer Dirk Huebner brings nearly three decades of clinical development experience in oncology.
Immunotherapy by Alex Robertson
Recent Developments and News
On November 25, 2025, the U.S. Securities and Exchange Commission (SEC) declared effective Aptevo’s Form S-1 registration statement, enabling the company to raise up to $25 million under a Standby Equity Purchase Agreement with YA II PN, Ltd. That same day, a Rule 424(b)(4) prospectus detailed the sale of 6,903,755 shares of common stock at $1.18 per share (pre-split basis), following a 1-for-20 reverse stock split effective May 23, 2025.
On December 9, 2025, Aptevo filed a Form 8-K; however, the filing did not disclose material financial metrics or strategic initiatives. In media appearances during December 2025, EVP & COO Jeff Lamothe and CEO Marvin White discussed mipletamig’s progress in a Phase 1b/2 trial for acute myelogenous leukemia and the expansion of Aptevo’s CRIS-7–derived CD3 portfolio on Bloomberg TV’s Small Stocks, Big Money.
Financial and Strategic Analysis
As of December 26, 2025, Aptevo’s share price stood at $0.6868, representing a 26.16% decline over the prior period, with daily trading volume of 742,624 shares on the NASDAQ. The absence of dividends and a low hiring score on third-party metrics highlight the company’s emphasis on R&D and capital preservation. The Standby Equity Purchase Agreement provides up to $25 million in funding over 36 months, subject to share issuance limitations and market conditions. This equity facility, along with collaboration agreements—such as the option pact with Alligator Bioscience AB to develop ALG.APV-527—forms a component of Aptevo’s financing and partnership strategy.
Market Position and Industry Context
Operating within the biotechnology research sector, Aptevo competes in the immuno-oncology landscape. Its pipeline includes mipletamig for hematologic malignancies and ALG.APV-527 for non-small cell lung cancer and other solid tumors, alongside preclinical candidates APVO603, APVO442, and APVO711. By focusing on multispecific antibody constructs, Aptevo aims to differentiate itself from monospecific antibody providers. Regulatory approvals, clinical trial outcomes, and strategic alliances will shape the company’s potential to capture market share in a field characterized by technological advancements and high development costs.
tl;dr
On November 25, 2025, the SEC declared effective Aptevo’s S-1 registration, unlocking up to $25 million via a standby equity purchase agreement. Following a 1-for-20 reverse stock split, shares traded at $0.6868 on December 26, 2025, down 26.16%. Clinical presentations on Bloomberg TV in December highlighted ongoing trials of mipletamig in AML and the expansion of the CD3-based bispecific portfolio. Near-term liquidity relies on equity availability and clinical readouts scheduled through 2026.
